08:48 AM EDT, 09/30/2024 (MT Newswires) -- BridgeBio Pharma ( BBIO ) said Monday it completed enrollment for the phase 3 study of BBP-418 intended for a certain type of muscular dystrophy.

The study is planned to have an interim analysis in 12 months, with the primary endpoint to be evaluated in 36 months, BridgeBio said.

If the trial is successful, BBP-418 could be the first approved disease-modifying therapy for Limb-girdle muscular dystrophy type 2I/R9, the company said.

Price: 25.27, Change: +0.33, Percent Change: +1.32